MX2022013557A - Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer. - Google Patents
Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer.Info
- Publication number
- MX2022013557A MX2022013557A MX2022013557A MX2022013557A MX2022013557A MX 2022013557 A MX2022013557 A MX 2022013557A MX 2022013557 A MX2022013557 A MX 2022013557A MX 2022013557 A MX2022013557 A MX 2022013557A MX 2022013557 A MX2022013557 A MX 2022013557A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination treatment
- antibody combination
- antibody
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960002621 pembrolizumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta descripción se refiere a métodos para tratar el cáncer mediante el uso de una combinación de un anticuerpo anti-CD40 tal como SEA-CD40 y un anticuerpo anti-PD-1 tal como pembrolizumab. El tratamiento puede incluir además una quimioterapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063016247P | 2020-04-27 | 2020-04-27 | |
PCT/US2021/029315 WO2021222188A1 (en) | 2020-04-27 | 2021-04-27 | Anti-cd40 antibody combination treatment for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013557A true MX2022013557A (es) | 2023-01-30 |
Family
ID=76035114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013557A MX2022013557A (es) | 2020-04-27 | 2021-04-27 | Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230203175A1 (es) |
EP (1) | EP4143230A1 (es) |
JP (1) | JP2023523869A (es) |
KR (1) | KR20230003081A (es) |
CN (1) | CN115667311A (es) |
AU (1) | AU2021262745A1 (es) |
BR (1) | BR112022021641A2 (es) |
CA (1) | CA3176974A1 (es) |
IL (1) | IL297657A (es) |
MX (1) | MX2022013557A (es) |
TW (1) | TW202206100A (es) |
WO (1) | WO2021222188A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023010080A1 (en) * | 2021-07-30 | 2023-02-02 | Seagen Inc. | Treatment for cancer |
WO2023247050A1 (en) * | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
ES2354865T3 (es) | 2005-05-26 | 2011-03-18 | Seattle Genetics, Inc. | Anticuerpos anti-cd40 humanizados y métodos para utilizarlos. |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
US20110223188A1 (en) | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
PL3212230T3 (pl) | 2014-10-29 | 2021-07-26 | Seagen Inc. | Dawkowanie i podawanie niefukozylowanych przeciwciał anty-CD40 |
-
2021
- 2021-04-26 TW TW110114992A patent/TW202206100A/zh unknown
- 2021-04-27 KR KR1020227041425A patent/KR20230003081A/ko active Search and Examination
- 2021-04-27 BR BR112022021641A patent/BR112022021641A2/pt unknown
- 2021-04-27 WO PCT/US2021/029315 patent/WO2021222188A1/en unknown
- 2021-04-27 US US17/921,521 patent/US20230203175A1/en active Pending
- 2021-04-27 CA CA3176974A patent/CA3176974A1/en active Pending
- 2021-04-27 AU AU2021262745A patent/AU2021262745A1/en active Pending
- 2021-04-27 JP JP2023509466A patent/JP2023523869A/ja active Pending
- 2021-04-27 IL IL297657A patent/IL297657A/en unknown
- 2021-04-27 MX MX2022013557A patent/MX2022013557A/es unknown
- 2021-04-27 CN CN202180039219.0A patent/CN115667311A/zh active Pending
- 2021-04-27 EP EP21727017.2A patent/EP4143230A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021222188A1 (en) | 2021-11-04 |
IL297657A (en) | 2022-12-01 |
EP4143230A1 (en) | 2023-03-08 |
TW202206100A (zh) | 2022-02-16 |
CA3176974A1 (en) | 2021-11-04 |
KR20230003081A (ko) | 2023-01-05 |
BR112022021641A2 (pt) | 2022-12-13 |
CN115667311A (zh) | 2023-01-31 |
JP2023523869A (ja) | 2023-06-07 |
AU2021262745A1 (en) | 2022-12-08 |
US20230203175A1 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
MX2022013557A (es) | Tratamiento combinado con anticuerpo anti-cd40 contra el cáncer. | |
MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
WO2018237148A8 (en) | Multispecific antibodies that target hiv gp120 and cd3 | |
MX2021014888A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda. | |
PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
EP3552665A3 (en) | Antibodies | |
MX2020012588A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos. | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
WO2018136617A3 (en) | Bacteria for treating cancer | |
PH12020500576A1 (en) | Method of treating cancers with antagonistic anti-pd-1 antibodies | |
MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
NZ736727A (en) | Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor | |
MX2021010916A (es) | Inhibidores rad51. | |
MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
MX2020010722A (es) | Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. | |
PH12020551453A1 (en) | Anti-cd25 for tumour specific cell depletion | |
MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
WO2016196373A8 (en) | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer | |
CR20200623A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
MX2019014291A (es) | Metodo de tratamiento. |